Back to Search Start Over

To Activate the Cath Lab?

Source :
Internal Medicine Alert. 12/15/2023, Vol. 45 Issue 23, p1-8. 8p.
Publication Year :
2023

Abstract

The article focuses on the U.S. Food and Drug Administration approval of tirzepatide for chronic weight management, previously approved for type 2 diabetes. Topics discussed include tirzepatide's dual action on GLP-1 and GIP receptors, potential advantages in weight reduction, and potential disadvantages such as Boxed Warning for thyroid C-cell tumors and adverse reactions.

Details

Language :
English
ISSN :
0195315X
Volume :
45
Issue :
23
Database :
Academic Search Index
Journal :
Internal Medicine Alert
Publication Type :
Periodical
Accession number :
174182476